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Abstract
Soft tissue sarcomas (STS) are rare, malignant tumors of mesenchymal origin
that manifest in the connective tissues, including muscle, adipose and deep skin tissue,
nerves, and joint tissue. Complications from primary or recurrent sarcomas often lead to
increased morbidity, but the most lethal aspect of sarcomas is their propensity for
hematogenous dissemination leading to metastatic disease. After development of distant
metastases, the median survival for patients with STS is merely 11 to 15 months1,2.
Therefore, gaining a better understanding of the metastatic environment is essential to
developing new therapies.

The tumor microenvironment

has been implicated as an

essential component for metastatic progression and one of the most prominent cell types
of the tumor microenvironment is the cancer-associated fibroblast (CAF)3,4. CAFs promote
tumor progression by stimulating angiogenesis, cancer cell growth, invasion and
metastasis, and through evasion of the immune response5,6. Studies clearly show the
importance of CAFs in tumor advancement; however, their origins have not been
conclusively determined, although multiple origins have been proposed7–12. Studies
previously conducted in our lab have demonstrated that hematopoietic stem cells (HSCs)
are a novel source for CAFs and their precursors in the blood, circulating fibroblast
precursors (CFPs)13. Our lab has further shown that murine CFPs are present in
peripheral blood, found in vivo in the tumor stroma, increase with tumor development, and
contribute to tumor growth, suggesting that CFPs play a direct role in promoting the
progression of solid tumors14. Additionally, studies from our lab revealed a HSC origin for
human CFPs15. The function of human CFPs in tumor metastasis, specifically STS,
however, has yet to be established.
Therefore, the goal of this study was to evaluate the peripheral blood of patients
with

STS

in

order

to

characterize

CFPs
iii

in

these

patients

and

determine

their role in promoting STS metastatic progression. In this study, peripheral blood was
collected from patients with STS and from normal control subjects. Our data has shown
that CFPs are present within the peripheral blood of patients with STS and normal control
subjects and that these cells display markers of fibroblasts, including collagen 1, alpha
smooth muscle actin, and vimentin. Our data have also shown that although there is no
significant difference in average number of CFPs present within the peripheral blood of
STS patients compared to normal control, evaluating individual results indicated that
patients with metastatic disease who are not on chemotherapeutic treatment may have
increased numbers of CFPs. We further showed that CFPs from patients with STS
contribute to sarcoma cell proliferation, migration, and invasion in vitro and that in vitro
generated tumor-exposed CFPs showed enhanced ability to contribute to sarcoma
invasion and displayed an altered cytokine profile when compared to control CFPs. Our
data indicate CFPs may play an important role in tumor progression and that through
further analysis, it may be discovered that these differences are subtype, tumor stage, and
treatment dependent.
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Chapter 1: Introduction
Section 1: Soft Tissue Sarcoma

1.1 Epidemiology and Etiology
Soft Tissue Sarcomas (STS) are rare, malignant tumors of mesenchymal origin.
They constitute 12% of pediatric cancers, but only 1% of all adult malignant neoplasms,
with a slight male predominance16,17. Three-fourths of STSs can be classified as either
undifferentiated

pleomorphic

sarcoma,

liposarcoma,

leiomyosarcoma,

myxofibrosarcoma, synovial sarcoma, or malignant peripheral nerve sheath tumor
(MPNST)18. It is estimated that 11,930 new cases of STS will be diagnosed in 2015,
along with 4,870 deaths19. The incidence according to age varies: embryonal
rhabdomyosarcoma occurs predominately in the pediatric population, while synovial
sarcoma occurs mostly in young adults, and undifferentiated pleomorphic sarcoma,
liposarcoma, leiomyosarcoma, and myxofibrosarcoma tend to occur in the elderly. In
similarity with other malignant tumors, the rate of adult STS increases with age- the
median diagnosis being around 65 years17.
Although the etiology of many soft tissue sarcomas is unknown, chemical
carcinogens, radiation, viral infection and immunodeficiency, or genetic susceptibility
have been associated with tumor development. Some studies have indicated there is
increased incidence of STS in those exposed to chlorophenols, phenoxyacetic
herbicides, and dioxin20,21. Other reports suggest breast cancer patients exposed to
radiation treatments are at increased risk of developing post-irradiation sarcoma22.
Additionally, patients with the retinoblastoma gene (RB1) germline mutation are at
elevated

risk

for

STS

(leiomyosarcoma,

malignant

fibrous

histiocytoma,

rhabdomyosarcoma, and liposarcoma) with statistically significant increases in STS in
1

patients treated with radiation, with the majority of STS occurring in the radiation field
after exposure23.

Viral infection and immunodeficiency play a prominent role in the

development of Kaposi sarcoma, which is clinically linked to Human Herpes Virus 8, a
gamma-herpes virus found to contain genes involved in evading the normal immune
response24,25. Genetic susceptibility is also known to be associated with elevated risk of
STS.

Li-Fraumeni syndrome, an autosomal dominant disease caused by germline

mutations of the TP53 tumor suppressor gene predisposes individuals to the
development of primary tumors at a young age. A study of 200 Li-Fraumeni syndrome
family members revealed that 17% of their primary cancers were diagnosed as STS26.
As stated previously, the retinoblastoma gene (RB1) is also associated with increased
risk of STS. Neurofibromatosis 1, an autosomal dominant disease caused by mutations
in the NF1 gene has been linked to certain STSs, including malignant peripheral nerve
sheath tumors, of which 50% have the NF1 mutation27.

1.2 Histopathology
Soft Tissue Sarcomas (STS) are an extremely diverse group of tumors- according to
the World Health Organization they comprise more than 100 different histological
subtypes17. STSs are classified according to their presumed origins and the diagnosis of
STS is based upon morphology along with immunohistochemical (IHC) staining. In
addition to IHC staining, Fluorescence In Situ Hybridization (FISH) is often used to
identify subtypes of STS containing chromosomal translocations, which one third of all
STSs are found to harbor (Table 1.1).
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Table 1.1 Soft Tissue Sarcoma Translocations
Diagnosis
Alveolar rhabdomyosarcoma

Alveolar soft part sarcoma
Clear cell sarcoma
Congenital fibrosarcoma/
Congenital mesoblastic
nephroma
Ewing’s sarcoma/
Peripheral primitive
neuroectodermal tumor

Low grade fibromyxoid sarcoma
Myxoid chondrosarcoma

Myxoid liposarcoma
Synovial Sarcoma

Common

IHC

stains

Chromosomal Abnormality
t(2;13)(q35;q14)
t(1;13)(p36;q14)
t(2;2)(p23;q36)
t(X;2)(q13;q36)
t(X;17)(p11.2;q25)

Genes Involved
PAX3-FKHR
PAX7-FKHR
PAX3–NCOA1
PAX3–FOXO4
TFE3-ASPL

t(12;22)(q13;q12)
t(2;22)(q33;q12)
t(12;15)(p13;q25)

EWS-ATF1
EWS1R–CREB1
ETV6-NTRK3

t(11;22)(q24;q12)
t(21;22)(q22;q12)
t(7;22)(p22;q12)
t(17;22)(q12;q12)
t(2;22)(q33;q12)
t(16;21)(p11;q22)
t(7;16)(q33;p11)
t(11;16)(p11;p11)
t(9;22)(q22;q12)
t(9;15)(q22;q21)
t(9;17)q22;q11)
t(12;16)(q13;p11)
t(12;22)(q13;q12)
t(X;18)(p11;q11)
t(X;18)(p11;q11)
t(X;18)(p11;q11)
t(X;20)(p11;q13)

EWS-FLI1
EWS-ERG
EWS-ETV1
EWS-FEV
EWS-E1AF
FUS-ERG
FUS-CREB3L2
FUS-CREB3L1
EWS-CHN
TFC12-CHN
TAF2N-CHN
TLS-CHOP
EWS-CHOP
SSX1-SYT
SSX2-SYT
SSX4-SYT
SSX1-SS181

include

desmin

to

identify

rhabdomyosarcoma

and

leiomyosarcoma (as one of multiple markers). S100 positivity correlates with cells arising
from the neural sheath and Factor VII identifies tumors of endothelial origin. Cytokeratin
staining can distinguish between synovial sarcoma and epithelioid sarcoma (both stain
positive) and fibrosarcoma (stains negative).

While some markers are more

characteristic than others, it is often necessary to examine a spectrum of markers in
order to determine histologic subtype.
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As stated above, the most frequent subtypes of STS include: undifferentiated
sarcoma, liposarcoma, leiomyosarcoma, myxofibrosarcoma, synovial sarcoma, and
malignant peripheral nerve sheath tumor, all of which have distinct characteristics.
Undifferentiated sarcoma, previously called malignant fibrous histiocytoma, is the most
common subtype of STS. This subtype refers to sarcomas that lack specific lines of
differentiation and may be further divided into pleomorphic, round cell, and spindle cell
variants. Liposarcomas are believed to be derived from precursors of adipocytes and are
commonly found in the extremities and retroperitoneum. The three main subgroups of
liposarcoma are well-differentiated/dedifferentiated, myxoid/round cell, and pleomorphic.
Myxoid liposarcomas typically reveal a FUS-CHOP or TLS-CHOP translocation28,29.
Well-differentiated/dedifferentiated almost invariably express diffuse nuclear MDM2
and/or CDK4, whereas pleomorphic liposarcomas are negative for expression30.
Leiomyosarcomas show pure smooth-muscle differentiation and are found in the
retroperitoneum, veins, and uterus. Synovial sarcomas histologically resemble synovial
cells, however their origin is unknown. Synovial sarcomas are characterized by
translocations of the SYT gene on chromosome 18 to SSX1, SSX2, or SSX4 on the X
chromosome31. Lastly, MPNST are commonly found in the trunk, extremities, head, and
neck. Diagnosis is difficult due to varied histomorphology and although S100 positivity is
often found, it is not uniformly expressed.

1.3 Clinical Presentation
STS manifests in the connective tissues (striated skeletal and smooth muscle,
tendons, adipose tissue, fibrous tissue, blood vessels, peripheral nerves, and the lining
of the joints) and often presents as a gradually enlarging, painless mass. While some
patients complain of pain or edema in an extremity due to compression by the tumor
4

mass, it is rare for a patient to present with constitutional symptoms of fever or weight
loss. STSs most prevalently occur in the extremities (75%), followed by the trunk wall
(10%), and the retroperitoneum (10%). These tumors have the capacity to become quite
large, particularly in the thigh and retroperitoneum, and growth rates vary depending
upon tumor aggressiveness.

Their common pattern of spread is hematogenous,

predominately to the lung, whereas spread to regional lymph nodes is infrequent,
excluding a few histological subtypes (rhabdomyosarcoma, synovial sarcoma, epithelioid
sarcoma, clear cell sarcoma, and the vascular sarcomas)32,33.

1.4 Diagnosis, Grading, and Staging
Due to their rarity and usually asymptomatic presentation, STSs tend to be initially
misdiagnosed, exacerbating their malignant potential. Further causation of diagnostic
and therapeutic challenges is the heterogeneity of these tumors, which are comprised of
more than 100 different histological subtypes17. Because STS is rare and often
unsuspected, multiple diagnostic tests should be performed to verify presence of STS.
To distinguish between a benign soft tissue mass and STS, the United Kingdom
Department of Health published criteria for urgent referral of patients with soft tissue
lesions. The criteria includes a soft tissue mass greater than 5 cm, painful lump, lump
that is increasing in size, a lump of any size that is deep to the muscle fascia, or
recurrence of a lump after previous excision34. After referral, imaging techniques should
be performed to assess tumor location and size in order to aid in surgical planning. MRI
is preferred for imaging masses of the extremities, head, trunk, and neck, while CT is
useful for imaging abdominal, visceral, or retroperitoneal masses. A core needle biopsy
or incisional biopsy of the tumor should also be performed for histological examination to
aid in determination of STS subtype and grade. The less invasive method of a core
5

needle biopsy is preferred and has shown efficacy for accurately determining the
subtype of STS in 88% of patients, whereas, incisional biopsy is often employed when
more tumor tissue is needed for the use of molecular analysis, flow cytometry, or
cytogenetics35. Furthermore, PET imaging, can distinguish benign tumors from
sarcomas, having the greatest sensitivity for high grade tumors. Lastly, due to the
propensity for STS lung metastasis, a chest CT scan is recommended after diagnosis of
STS to discern whether pulmonary nodules are present. Similarly, patients with known
angiosarcoma should undergo brain imaging due to this tumor’s propensity for
metastatic spread to the central nervous system.
Tumor grade, which should only be applied to untreated primary STSs, is indicative
of how likely a tumor is to grow and disseminate and thus it is an important factor when
planning treatment regimens. The two most predominant systems for grading STSs are
those proposed by the National Cancer Institute and the Fédération Nationale des
Centres de Lutte Contre le Cancer (FNCLCC). The FNCLCC is more precisely defined
and has revealed greater efficacy, therefore it is the preferred system. However, grading
is not valuable for the prognosis of all STS subtypes. Subtypes excluded from grading
are MPNST, angiosarcoma, alveolar soft part sarcoma, extraskeletal myxoid
chondrosarcoma, clear cell sarcoma, and epithelioid sarcoma. Three prognostic factors
are used for defining tumor grade according to FNCLCC: tumor differentiation, mitotic
count, and tumor necrosis (Table 1.2).
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Table 1.2 FNCLCC Histological Grading System
Histological Parameter
Tumor Differentiation






Mitotic Count
(1 HPF measures 0.1734 mm2)
Tumor Necrosis

Histological Grade











Definition
Score 1: Sarcomas closely resembling
normal adult mesenchymal tissue and
potentially difficult to distinguish from the
counterpart benign tumor (e.g. welldifferentiated liposarcoma, well-differentiated
leiomyosarcoma)
Score 2: Sarcomas for which histological
typing is certain (e.g. myxoid liposarcoma,
myxofibrosarcoma)
Score 3: Embryonal and undifferentiated
sarcomas, synovial sarcomas, sarcomas of
doubtful type
Score 1: 0-9 mitoses per 10 HPF
Score 2: 10-19 mitoses per 10 HPF
Score 3: >19 mitoses per 10 HPF
Score 0: No necrosis
Score 1: <50% tumor necrosis
Score 2: ≥50% tumor necrosis
Grade 1: total score 2, 3
Grade 2: total score 4, 5
Grade 3: total score 6, 7, 8

While tumor grade is indicative of tumor aggressiveness, tumor stage determines the
size of the primary tumor and the extent to which the tumor has already spread. The
staging system most commonly used for STS is the TNM system created by the
International Union for Cancer and the American Joint Committee on Cancer (AJCC)36.
The TNM staging system incorporates four factors: tumor size and depth (T), lymph
node involvement (N), distant metastasis (M), and histologic grade (G) (Table 1.3).
STSs of the extremities and trunk are staged with the TNM system; however, an
alternate system should be used for STSs of the retroperitoneum as other factors
including histology, metastasis, and resection margins are more prognostic.
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Table 1.3 AJCC’s TNM Staging System
Primary Tumor (T)

TX
T0
T1

T2

Regional Lymph
Nodes (N)
Distant Metastasis
(M)
Histologic Grade
(G)

Anatomic
Stage/Prognostic
Groups




T1a
T1b




T2a
T2b

NX
N0
N1
M0
M1
GX
G1
G2
G3
Stage IA
Stage IB
Stage IIA
Stage IIB
Stage III
Stage IV

Primary tumor cannot be assessed
No evidence of primary tumor
Tumor 5 cm or less in greatest dimension
 Superficial tumor
 Deep tumor
Tumor more than 5 cm in greatest dimension
 Superficial tumor
 Deep tumor
Regional lymph nodes cannot be assessed
No regional lymph node metastasis
Regional lymph node metastasis
No distant metastasis
Distant metastasis
Grade cannot be assessed
Grade 1
Grade 2
Grade 3
T1a

N0

M0

G1, GX

T1b

N0

M0

G1, GX

T2a

N0

M0

G1, GX

T2b

N0

M0

G1, GX

T1a

N0

M0

G2, G3

T1b

N0

M0

G2, G3

T2a

N0

M0

G2

T2b

N0

M0

G2

T2a, T2b

N0

M0

G3

Any T

N1

M0

Any G

Any T

Any N

M1

Any G
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1.5 Treatment
The goal of any treatment plan is to minimize tumor recurrence, while maintaining
function and quality of life for the patient. Due to STS heterogeneity, treatment plans
vary based on subtype and extent of disease. According to the National Comprehensive
Cancer Network (NCCN) guidelines, surgical resection is an essential component of
treatment for primary low grade STS tumors of the extremities and trunk wall37. Efforts
to achieve a complete resection with negative margins of at least 1 cm should be made,
but if tumor margins are close, the addition of adjuvant radiation therapy is
recommended. When primary tumors are intermediate to high grade, greater than 5 cm
in size, or deep, the addition of radiation therapy is also recommended. For patients
with high grade primary tumors, the NCCN recommends resection alone or along with
the following: pre-operative radiation therapy, post-operative radiation therapy,
neoadjuvant chemotherapy, or adjuvant chemotherapy.
Radiation therapy (RT) dose is dependent upon tissue location and tolerance.
Newer

techniques,

including

intensity modulated RT,

intraoperative RT,

and

brachytherapy have demonstrated improved outcomes in STS patients38–40. Intensity
modulated RT is beneficial for its ability to reduce exposure of normal tissue surrounding
the tumor to high dose radiation, whereas intraoperative RT is a process in which
radiation treatment occurs during surgery. Brachytherapy is the use of radioactive seeds,
which are implanted into the tumor bed through the use of catheters and can include
low-dose rate, fractionated high-dose rate, or intraoperative high-dose rate therapy.
Although the value of chemotherapy remains a subject of considerable debate,
distinct STS histologies have shown chemosensitivity to certain regimens, thus,
chemotherapy should be prescribed based upon STS subtype and location. The
pediatric Ewing sarcomas and alveolar/embryonal rhabdomyosarcomas are routinely
9

treated with neoadjuvant chemotherapy (vincristine, cyclophosphamide, doxorubicin)
due to their high risk for metastasis and sensitivity to chemotherapy. Synovial sarcoma
is another chemosensitive tumor, with progression-free survival (PFS) response rates for
combination therapy of ifosfamide and doxorubicin showing 58% in one study41. For
patients with leiomyosarcoma, gemcitabine and docetaxel combination therapy has
shown PFS rates of 16%42. Yondelis, a more recently developed synthetic
chemotherapeutic drug originally derived from the marine tunicate ecteinascidia
turbinata, has shown PFS rates of up to 51% in patients with liposarcoma and
leiomyosarcoma43.
Current treatment for patients with metastatic disease often comprises resection,
radiation therapy, and/or chemotherapy. First line chemotherapeutic treatments include
ifosfamide (alkylating agent) and doxorubicin (anthracyclin antibiotic), which have proven
the most active against metastatic soft tissue sarcomas, yet still maintain paltry response
rates observed in only 15-35% of patients44,45. Single agent chemotherapy regimens that
should be considered are doxorubicin, epirubicin, and ifosfamide, which have shown
response rates in metastatic STS46,47. Combination chemotherapy regimens consist of
AIM (adriamycin, ifosfamide, and mesna); MAID (mesna, adriamycin, ifosfamide, and
dacarbazine); gemcitabine with either docetaxel, vinorelbine, or dacarbazine; and
doxorubicin along with dacarbazine. For many patients with metastatic soft tissue
sarcoma, chemotherapy is used with palliative intent- to reduce tumor burden, slow
disease progression, and improve symptoms.

While some studies have shown

enhanced PFS, no studies have shown significant overall survival improvement and
potential benefits may be offset by treatment-related toxicities, especially upon use of
combination chemotherapy48–50. Yet, molecular pathogenesis has provided key insight
towards developing novel chemotherapeutic treatments. For example, patients with ckit
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positive gastrointestinal stromal tumors have shown 70% PFS rates for 12 months after
treatment with Imatinib, a tyrosine kinase inhibitor known to inhibit ckit, depicting
increased effectiveness of targeted therapies51. The effectiveness of targeted therapies
in comparison to alkylating or intercalating agents reinstates the need to uncover specific
molecular markers that can be utilized to develop more compelling chemotherapeutic
agents. Additionally, because STS chemotherapeutic agents exhibit varied PFS rates, it
is a challenge for physicians to identify which patients will benefit from treatment, thus,
markers to assess chemotherapeutic efficacy in patients with certain types of STS must
be determined. These prognostic markers may then identify which patients will benefit
from potential chemotherapeutic regimens, while sparing those who will not benefit from
possible toxicity-related treatment problems.

1.6 Clinical Outcomes
Multiple studies have shown that tumor size, stage, and histologic grade are
important indicators of clinical outcome for patients with STS52–54. In one study of over
1000 patients with STS of the extremities, it was found that being over the age of 50 and
having positive resected margins predicted local recurrence, while tumor grade and size
were the main predictors of distant recurrence and survival53. Other factors associated
with survival include age, histologic subtype, and anatomic site55.
For STS patients who are successfully treated of their primary tumor, approximately
25% will go on to develop metastatic disease and once the primary tumor exceeds 5 cm
in size, is deep to the fascia, and intermediate or high grade, the incidence of metastasis
increases to 40-50%56,57. Furthermore, approximately 10% of patients have detectable
metastases at primary tumor diagnosis and the majority of patients with metastatic
disease are incurable17. Thus, metastasis, via hematogenous dissemination, remains
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one of the most lethal aspects of soft tissue sarcomas and constitutes the greatest
obstacle towards effective treatment and positive clinical outcomes.
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Section 2: Tumor Microenvironment in Metastasis
2.1 Tumor Microenvironment (TME)
The TME is pivotal to cancer progression, as it establishes a permissive and
supportive environment for the cancer cell. It consists of extracellular matrix
components (collagen, elastin, fibrilin, fibronectin, and proteoglycans), cellular
components (immune cells, endothelial cells, adipocytes, fibroblasts), nerves, and
vasculature all within close proximity to the malignant cancer cells.
Dvorak first observed that the tumor microenvironment contains striking
similarities to that of an active wound and, thus, described tumors as “wounds that do
not heal”58. During the normal wounding process, quiescent fibroblasts undergo
activation to become myofibroblasts, producing alpha-smooth muscle actin (α-SMA), an
important component of the cytoskeleton involved in cell contractility and motility59.
Additionally, these activated fibroblasts promote angiogenesis and secrete a complex
extracellular matrix (ECM) to further assist in repairing the damaged tissue.

After

completing reparation of the wound, activated fibroblasts undergo programmed cell
death and are eliminated from the granulation tissue, whereas during tumor progression,
fibroblasts in the TME are consistently present in the tumor stroma, remain perpetually
activated, and are not removed by apoptosis60.

2.2 Cancer-Associated Fibroblasts (CAFs)
The most prominent cell type of the TME is the cancer-associated fibroblast
(CAF)34. CAFs are mature, activated tissue fibroblasts associated with the solid tumor,
which promote tumor progression by stimulating angiogenesis, cancer cell growth,
invasion and metastasis, and through evasion of the immune response56. They are
activated by tumor cell secretion and stromal cell secretion of TGF-β1, which has been
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shown to mediate α-SMA production, a marker of activated fibroblasts61. Through
production of chemokines and growth factors such as fibroblast growth factor 2 (FGF-2),
stromal-derived cell factor 1 (SDF-1), vascular endothelial growth factor (VEGF),
hepatocyte growth factor (HGF), insulin-like growth factor (IGF), and epidermal growth
factor (EGF), CAFs implement a direct effect upon promotion of growth in the
surrounding epithelium and upon angiogenesis in the tumor stroma62. CAFs are also an
important source of tumor inflammatory cytokines such as interleukin-1β (IL1-β)63. They
participate in remodeling of the extracellular matrix by secretion of collagen type 1 and
fibronectin, ECM proteins correlated with tumor stroma stiffening and enhanced
metastatic potential64,65. Tumor stroma stiffening, which is associated with more efficient
TGF-β activation, may create a positive feedback loop through enhancing fibroblast
activation and ECM synthesis, leading to increased matrix rigidity66,67.

CAFs are

additionally a source for matrix-metalloproteinases (MMP)-2,-3, and -9, which degrade
the ECM, potentiating tumor cell migration, invasion, and metastasis, and creating a
pathway for angiogenesis62. Furthermore, CAFs secrete chemokines exploited by tumor
cells to aid in their metastatic potential. During hypoxic conditions, tumor cells increase
CXCR4 expression, enabling them to escape to a normoxic environment by migration
towards SDF1/CXCL12-expressing CAFs; these SDF1/CXCL12-expressing CAFs
additionally recruit endothelial-progenitor cells from the bone marrow that differentiate
into tumor-associated vascular endothelial cells, which lay the foundation for angiogenic
growth68,69. CAFs have also been shown to be involved in chemotherapeutic resistance.
With the secretion of ECM proteins, CAFs contribute to tumor ECM rigidity, causing
increased interstitial fluid pressures, resulting in diminished chemotherapeutic delivery to
the tumor64. Additionally, ECM rigidity has been associated with TGF-β1 tumorigenic
functions, including EMT and cell motility70. Other studies have shown that activated
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fibroblasts are capable of preventing apoptosis of melanoma cells following cisplatin
treatment71.

Factors secreted by CAFs, including HGF, have been implicated in

promoting chemotherapeutic resistance by inhibiting drug induced apoptosis72. Studies
clearly show the importance of CAFs in tumor advancement; however, their origin has
not been conclusively determined.

2.3 HSC-Derived Circulating Fibroblast Precursors
Various origins for cancer-associated fibroblasts (CAFs) have been proposed,
including resident tissue fibroblasts, smooth muscle cells, epithelial to mesenchymal
transition, endothelial cells, and bone marrow-derived mesenchymal stromal cells

7–12

.

Yet, our studies, based upon a murine single hematopoietic stem cell transplantation
model have demonstrated an additional, novel hematopoietic stem cell (HSC) source for
CAFs and their precursors in the blood, circulating fibroblast precursors (CFPs)13.
The HSC transplant method performed by our group is essential for the
identification of HSC-derived cells in various murine disease models. In our transplant
method, bone marrow is obtained from mice that ubiquitously express enhanced green
fluorescent protein (EGFP) on a B6.SJL-Ptprcb Pep3b/BoyJ (C57BL/6-CD45.2)
background.

The EGFP+ bone marrow then undergoes flow cytometric cell sorting

using markers of HSCs (Lineage-, Sca-1+, ckithi, CD34-, side population), with Lineagedenoting cells that are negative for markers of B cells, T cells, granulocytes, and
erythrocytes. Single cells are sorted into each well of a 96 well plate and undergo short
term culture. Because the majority of HSCs remain in G0 for up to 3-4 days after
initiation of cell culture, we select clones consisting of 20 or fewer cells after one week
incubation (as clones consisting of greater than 20 cells are likely hematopoietic
progenitor cells that do not remain quiescent for the initial 3-4 days in culture)73. This
15

clonal population of putative HSCs recovered from the wells is then intravenously
injected into a black syngeneic B6.SJL-Ptprca Pep3b/BoyJ (C57BL/6-CD45.1) mouse (in
order to distinguish donor from recipient, which can be done by examining presence or
absence of EGFP or CD45.1 expression) whose bone marrow has been ablated through
lethal irradiation. After 2 months, the mice are checked for multilineage engraftment.
The defining property of a HSC is in its ability to repopulate the bone marrow and
reconstitute hematopoiesis following transplantation, thus the presence of multilineage
engraftment unequivocally indicates an HSC origin for any EGFP+ cell in our
transplanted mice.
Our group employed this HSC transplant method to reveal that EGFP+ cells
derived from the bone marrow of clonally engrafted mice gave rise to fibroblasts in vitro
and expressed procollagen 1-α1, discoidin domain receptor 2 (DDR2, receptor for
collagen), vimentin, and fibronectin mRNA, all markers of fibroblasts74.

In murine

melanoma and Lewis lung carcinoma tumor models, our group previously identified
HSC-derived EGFP+ cells that incorporated into the tumor stroma and gave rise to cells
phenotypically resembling fibroblasts in the tumor capsule13. Further analysis revealed
these cells expressed type 1 procollagen and α-SMA, indicating that these HSC-derived
cells in the tumor stroma were indeed fibroblasts, specifically activated fibroblasts 13. Our
group then went on to examine whether the circulating precursors to these fibroblasts
homed to and were present within the tumor stroma. CFPs were found in vivo in the
tumor stroma, most interestingly within the tumor blood vessels and it was determined
that these CFPs were of HSC origin and could be defined as CD45+ DDR2+ cells
expressing markers associated with the monocyte lineage14. CFP number increased in
correlation with tumor progression and CFPs were shown to migrate in response to
tumor-conditioned media14. Additionally, CFPs were found to express chemokine
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receptor type 2 (CCR2), a receptor for monocyte chemoattractant protein 1 (MCP-1),
and it was further found that CFP migration was MCP-1 dependent14. This research
clearly revealed a HSC origin for murine CFPs and suggested their role in tumor
progression; however, the identification of human HSC-derived CFPs had yet to be
studied.
To examine the origin of human CFPs, our group obtained peripheral blood from
human subjects, then cultured and stained the cells for fibroblast markers. It was found
that peripheral blood mononuclear cells stained positive for αSMA, pro-collagen type 1,
vimentin, and 5B5, all markers of fibroblasts15. A subsequent study was performed on
peripheral blood obtained from three female subjects transplanted with GCSF-mobilized
stem cells from male donors15. Non-adherent mononuclear cells derived from the
peripheral blood of the female subjects were cultured and fluorescence in situ
hybridization (FISH) analysis revealed the presence of both X and Y chromosomes in all
cultured cells, indicating the donor origin of CFPs. Although this study revealed the
donor origin of human CFPs, further evidence was needed to unequivocally show an
HSC origin for CFPs. An additional study was performed on the peripheral blood of two
untreated patients with Philadelphia chromosome positive chronic myelogenous
leukemia (CML). The Philadelphia chromosome occurs when chromosomes 9 and 22
translocate, resulting in the fusion of the BCR and C-ABL genes. FISH analysis for the
BCR/ABL translocation on cultured non-adherent mononuclear cells revealed the
presence of the BCR-ABL translocation. Because CML is a clonal disorder of the HSC,
the presence of the BCR-ABL translocation strongly indicates a HSC origin for human
CFPs.
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Chapter 2: Rationale, Hypothesis, and Specific Aims
Rationale
Our studies, based upon a murine single hematopoietic stem cell transplantation
model have demonstrated that hematopoietic stem cells (HSCs) are a novel source for
cancer-associated fibroblasts (CAFs) and their blood precursors, circulating fibroblast
precursors (CFPs). Our research has shown that murine CFPs (CD45+ DDR2+) are
present in the peripheral blood and increase with tumor burden, implicating their
importance in tumor progression. Our lab has also uncovered an HSC origin for human
CFPs.

However, the identification and characterization of human CFPs in cancer,

specifically soft tissue sarcoma, has yet to be established.

Preliminary evidence from

our lab suggests we are capable of isolating CFPs from human peripheral blood and
once cultured, CFPs exhibit markers of fibroblasts.
Cancer-associated fibroblasts (CAFs), potentially derived from circulating
fibroblast precursors (CFPs), are mature tissue fibroblasts associated with the solid
tumor and have been shown to promote tumor progression by stimulating angiogenesis,
cancer cell growth, invasion and metastasis, and through evasion of the immune
response. CAFs implement these effects by production of various growth factors (such
as VEGF, a potent angiogenesis inducer), matrix metalloproteinases (such as MMP9
which degrades collagen and fibronectin, allowing the tumor cell to transverse the
basement membrane), and through production of chemokines and cytokines. Our lab
has shown that CFPs, a precursor to CAFs, increase with tumor burden, are present in
the tumor stroma, and migrate in response to tumor conditioned media, suggesting that
CFPs may play a direct role in promoting the progression and metastasis of solid
tumors. Additionally, no studies have investigated the role of CAFs in soft tissue
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sarcoma progression. We are therefore interested in uncovering whether CFP-derived
fibroblasts play a functional role in soft tissue sarcoma metastasis through production of
specific chemokine, cytokine, and growth factors involved in promoting the proliferation,
migration, and invasion of sarcoma cells.

Hypothesis
HSC-derived CFPs are present in patients with soft tissue sarcoma and promote soft
tissue sarcoma tumor cell proliferation, migration, and invasion in vitro.

Specific Aims
Aim 1: To isolate, characterize, and quantify circulating fibroblast precursors
(CFPs) in patients with soft tissue sarcoma through analysis of hematopoietic and
fibroblastic marker expression. Mononuclear cells were isolated via ultra-density
centrifugation from peripheral blood and utilized immediately or cultured for growth of
fibroblasts and examined for presence of hematopoietic and fibroblastic markers by
immunofluorescence, flow cytometry, and quantitative real-time polymerase chain
reaction.

Aim 2: To determine the role of CFP-derived fibroblasts from patients with soft
tissue sarcoma in promoting proliferation, migration, and invasion of sarcoma
cells. The ability of CFP-derived fibroblasts to promote proliferation was assessed via
Cyquant Direct Cell assay and ability to promote migration and invasion was assessed
via transwell assays. CFPs were tested for production of chemokine, cytokine, and
growth factors associated with metastatic progression (i.e. ability to promote
proliferation, migration, and invasion of sarcoma cells) via antibody array.
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Figure 1. Specific Aims. Aim 1: To isolate, characterize, and quantify circulating
fibroblast precursors (CFPs) in patients with soft tissue sarcoma through analysis of
hematopoietic and fibroblastic marker expression. Aim 2: To determine the role of CFPderived fibroblasts from patients with soft tissue sarcoma in promoting proliferation,
migration, and invasion of sarcoma cells.

20

Chapter 3: Significance
90% of all cancer deaths are due to metastatic disease, making it the single most
significant challenge to management of patients with malignant neoplasms. Patients
with metastatic soft tissue sarcomas have a five year survival rate of 16% and only 1535% of patients respond to standard chemotherapeutic regimens44,45,75. Although many
chemotherapeutic agents target the tumor cell, few agents target the tumor stroma even
though it is an essential component of the tumor, providing a supportive and permissive
habitat for tumor progression. Cancer-associated fibroblasts (CAFs) are the most
abundant cell type of the tumor microenvironment and promote metastasis through
production of factors that support tumor cell growth, vascularization, migration and
invasion, escape from immune response, and chemotherapeutic drug resistance62.
While multiple origins for CAFs have been proposed, our group has shown a
hematopoietic stem cell (HSC)-derived circulating fibroblast precursor (CFP) origin for
CAFs13. This HSC-derived CFP origin for CAFs is especially pertinent in the realm of
soft tissue sarcomas that have a predilection towards hematogenous dissemination.
Studies have demonstrated the ability of bone marrow derived cells to colonize premetastatic sites prior to tumor cell colonization, further implicating a role of HSC-derived
cells from the bone marrow in metastatic progression65. Our research will elucidate the
effects of HSC-derived CFPs on soft tissue sarcoma metastasis, potentially identifying
novel factors responsible for disease progression.

Furthermore, once CFPs are

implicated in soft tissue sarcoma metastasis, they may serve as unique therapeutic
targets. Additionally, the known HSC-origin of CFPs may allow us to target CFPs at an
even earlier state, depleting all possible HSC-derived CFPs that have the potential to
differentiate into CAFs within the tumor microenvironment.
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Conclusively, the key to uncovering new therapies for treating advanced cancers,
such as metastatic soft tissue sarcoma, lies in the enhanced understanding of their
metastatic environment. Our studies will result in a better understanding of human tumor
metastasis, specifically through CFP marker expression profiling and discovery of the
role of CFPs in promoting sarcoma tumor cell proliferation, migration, and invasion. Our
studies may then lead to the identification of unique CFP-based therapies for soft tissue
sarcoma metastasis inhibition.
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Chapter 4: Specific Aim 1
To isolate, characterize, and quantify CFPs in patients with soft tissue sarcoma through
analysis of hematopoietic and fibroblastic marker expression.

Section 1: Introduction
Previous studies in our lab, based upon a murine single hematopoietic stem cell
transplantation model have demonstrated that hematopoietic stem cells (HSCs) are a
novel source for cancer-associated fibroblasts (CAFs) and their blood precursors,
circulating fibroblast precursors (CFPs)13. Our lab’s research has shown that murine
CFPs (CD45+ DDR2+) are present in the peripheral blood and increase with tumor
burden14. Our lab has also uncovered a HSC origin for human CFPs15. However, the
identification and characterization of human CFPs in cancer, specifically soft tissue
sarcoma, has yet to be established. CFP classification is based upon expression of
markers that recognize both their hematopoietic origins and fibroblastic traits, thus we
define CFPs as peripheral blood cells expressing the hematopoietic cell marker CD45
(common leukocyte antigen) along with the fibroblast marker, discoidin domain receptor
2 (DDR2, collagen receptor). Collagen type I, another marker of fibroblasts was also
examined. Because CFPs have the potential to differentiate into activated CAFs in the
tumor microenvironment, further examination of markers of activated fibroblasts was
conducted; these included vimentin and alpha-smooth muscle actin (α-SMA).

Section 2: Hypothesis
We hypothesized that CFPs were present in the peripheral blood of patients with soft
tissue sarcoma and displayed hematopoietic and fibroblastic marker expression profiles.
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Section 3: Materials and Methods
Cell Culture of Human Peripheral Blood
Peripheral blood (9-15 mL) was drawn from patients with soft tissue sarcoma and
from control subjects (All Cells #WB001-NH) without any known malignancies and
collected in sodium heparin-coated vacutainer tubes (BD #367878). Mononuclear cells
were isolated via density centrifugation with Lympholyte H (Cedarlane #CL5010) and
either frozen for later analysis or plated on a T25 tissue culture treated flask (Corning
#430639) and incubated at 37°C in free gas exchange at 5% CO2. After a 20 hour
incubation period, non-adherent HSC-derived mononuclear cells were removed and
plated on 4-well fibronectin-coated tissue culture plates (Corning #354559) for 14-21
days at a concentration of 6x105 cells per well in 1 mL of Minimum Essential Medium α
(MEMα) (Life Technologies #12561) supplemented with 20% fetal bovine serum (Atlanta
Biologicals, lot #6005C) and penicillin streptomycin in order to promote the differentiation
of CFPs into fibroblasts (CFP-derived fibroblasts). The rationale for obtaining the nonadherent population of mononuclear cells is derived from the concept that two types of
stem cells are present in the bone marrow- hematopoietic stem cells (HSCs) and
mesenchymal stem/stromal cells (MSCs). MSCs are characterized by their ability to
adhere to plastic, thus, we obtain the non-adherent population in order to enrich for
HSC-derived cells76.

Cell Culture of HT-1080 and HFF-1 cells
The human HT-1080 fibrosarcoma and HFF-1 foreskin fibroblast cell lines were
purchased from American Type Culture Collection (ATCC). HT-1080 cells (ATCC #CCL121) were cultured in Eagle’s Minimum Essential Medium (ATCC #30-2003)
supplemented with 10% Fetal Bovine Serum (ATCC #30-2020) and HFF-1 cells (ATCC
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#SCRC-1041) were cultured in Dulbecco’s Modified Eagle’s Medium (ATCC #30-2002)
supplemented with 15% Fetal Bovine Serum (ATCC #30-2020). Both cell lines were
incubated at 37°C in free gas exchange at 5% CO2 and allowed to grow to confluency
before splitting. Cell lines were used below passage 8.

Immunofluorescence Staining
Antibodies were first titrated and tested on cultured HFF-1 fibroblast cells in order
to optimize our staining methods for fibroblast markers (Figure 2).
After 14-21 days culture, CFP-derived fibroblasts were washed in phosphate
buffered saline (PBS), then fixed with 4% paraformaldehyde and stored in 0.05% sodium
azide until ready for staining. Cells were then washed 3 times with PBS. 0.02% Triton X
was added for 20 minutes, then cells were again washed 3 times with PBS. Cells were
then blocked for 1 hour in 5% donkey serum in 3% bovine serum albumin/PBS. Primary
antibodies for alpha smooth muscle actin (αSMA), Collagen 1, and Vimentin (Table 4.1)
were added and incubated overnight at 4°C. Cells were washed 3 times with PBS and
secondary antibodies for Cyanine 3 (Cy3) and Fluorescin Isothiocyanate (FITC)
(Table 4.1) were added for 1 hour, incubated at room temperature and protected from
light. Cells were washed 3 times with PBS, then Hoechst 33342 (Invitrogen #H3570)
diluted 1:25000 in PBS was added for 8 minutes. Fluorogel (Electron Microscopy
Sciences #17985-10) was then added before slides were coverslipped. Slides stained
with Secondary only were used as controls for non-specific antibody staining.
Epifluorescence and differential contrast (DIC) microscopy was conducted using a Nikon
Eclipse 90i microscope with NIS Elements AR3.2 Software. Images were processed
using Adobe Photoshop CS2 (Adobe Systems, Inc., San Jose, CA).

25

Hoechst

Merge

Merge
Magnified

A-D: αSMA

E-H: Col I

I-L:
Secondary
Only
M-P:
Vimentin

Q-T:
Secondary
Only

Figure 2. Immunohistochemical standardization of staining for fibroblast markers.
Optimization of antibody staining for activated fibroblast markers, including αSMA
(red; A-D), Col I (red; E-H), and Vimentin (green; M-P), with cultured human foreskin
fibroblast (HFF-1) cells. Nuclei were stained with Hoechst dye (blue). Secondary only
control staining for αSMA/Col I (I-L) and Vimentin (Q-T). Mag bars in A-T = 25 µm.

Table 4.1 Antibodies Used for Immunofluorescence Staining
Antibody
Rabbit αSMA
Mouse Collagen 1
Rabbit Collagen 1
Mouse Vimentin
Donkey anti Rabbit-Cy3
Donkey anti Mouse-FITC

Company
Abcam
Abcam
Abcam
Abcam
Jackson
Jackson

Catalog #
ab15734
ab90395
ab34710
ab8979
715-165-152
711-096-150
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Lot #
GR110540-1
GR117081-1
GR33585-2
GR39704
109623
106884

Concentration
1:50 in PBS
1:50 in PBS
1:50 in PBS
1:50 in PBS
1:100 in PBS
1:100 in PBS

Flow Cytometry Staining
Antibodies were first titrated to determine optimal staining concentrations for flow
cytometric analysis.
After mononuclear cells were isolated from peripheral blood via density
centrifugation with Lympholyte H (Cedarlane #CL5010), they were washed, then
resuspended in cell culture freeze media with DMSO (Millipore #S002-5F), stored at
-80°C overnight, then placed in liquid Nitrogen storage until analysis. When ready for
analysis, cells were quickly thawed in a 37°C water bath, washed, then resuspended in
growth media and allowed to recover for 1 hour in an incubator at 37°C in free gas
exchange at 5% CO2. Cells were then counted with Trypan Blue for viability, washed,
and allocated into tubes for staining. Cells were resuspended in 100 μL phosphate
buffered saline (PBS), then 11 μL Human AB Serum (10% of cell suspension volume)
was added to block non-specific antibody binding. After 1 minute incubation, cells were
stained with CD45 and Discoidin Domain Receptor 2 (DDR2) antibodies (Table 4.2) and
incubated for 20 minutes on ice, protected from light. After washing, APC secondary
antibody was added and cells were incubated for 20 minutes on ice, protected from light.
Live/Dead

Fixable

Cell

Stain

(Invitrogen

#L-23102)

was

used

according

to

manufacturer’s protocol. Cells were acquired on BD LSR Fortessa Analytic Flow
Cytometer. Positive staining and gating strategy were determined by comparison to
isotype control or fluorescence minus one controls. Data were analyzed using FlowJo
software.
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Table 4.2 Antibodies Used for Flow Cytometry
Antibody
Mouse IgG1k
CD45-BV510
Mouse IgG2B DDR2
Rat anti Mouse
IgG2B APC

Company
Becton
Dickenson
R&D Systems
R&D Systems

Catalog #
563204

Lot #
3172808

Clone #
H130

MAB25381
F0133

CACM0112051
ACKM0113121

290804
332723

Quantitative Real-time PCR
Total RNA from cells was isolated using Trizol reagent (Life Technologies
#15596) in combination with the RNeasy Mini Kit (Qiagen #74104). 0.5 µg total RNA was
reverse transcribed in a 20 µL reaction using the iScript cDNA synthesis kit (Bio-Rad
#170-8890). Quantitative Real-time PCR was performed with 2.5 µL of a 1:20 dilution of
reverse-transcribed cDNA, along with SsoAdvanced Universal Probes Supermix (BioRad #172-5284) and primer-probe combinations (Table 4.3) designed through the
Universal ProbeLibrary Design Center (Roche) in a 10 µL reaction in the Light Cycler 96
(Roche). Cycling conditions were conducted according to the manufacturer’s protocol.
Reactions were run in triplicate for each cDNA sample, along with non-reverse
transcriptase and negative controls. Relative gene expression was quantified based on
Cq value measured against standard curves for each primer-probe set. Data were
normalized to HPRT reference gene.
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Table 4.3 Primer Sequences for RT-qPCR

Gene
CD45

GenBank
Accession #
Y00062.1

Primer
Sequence 5' to 3'
F: agtcaaagttattgttatgctgacaga
R: tgctttccttctccccagta

Coll1A1

NM_000088.3

F: gggattccctggacctaaag
R: ggaacacctcgctctcca

67

Vimentin

ENST00000224237.5

F: gaccagctaaccaacgacaaa
R: gaagcatctcctcctgcaat

39

αSMA

NM_001141945.1

F: ctgttccagccatccttcat
R: tcatgatgctgttgtaggtggt

58

DDR2

NM_006182.2

F: ggagagttcttccgagacca
R: aggacaaatggctggttgag

16

CD14

NM_000591.2

F: gttcggaagacttatcgaccat
R: acaaggttctggcgtggt

74

Coll5

NM_000093.3

F: cctggatgaggaggtgtttg
R: cggtggtccgagacaaag

42

CD11b

J03925.1

F: ggcatccgcaaagtggta
R: ggatcttaaaggcattctttcg

9

HPRT

ENST00000298556.7

F: gaccagtcaacaggggacat
R: gtgtcaattatatcttccacaatcaag
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Probe
54

Human Consent
Peripheral blood was obtained after informed consent was given and subjects
were enrolled into our Institutional Review Board approved study (CTO 101576) through
the MUSC Hollings Cancer Center. All subjects consented were over 18 years of age
and had soft tissue sarcoma, either metastatic or non-metastatic.

Statistical Data Analysis
Data are presented as mean ± standard deviation of the value. To compare
variables between 2 groups, the two-tailed unpaired Student t-test was performed in
Microsoft Excel, with significance determined as p<0.05.
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Section 4: Results
Enrichment of HSC-derived cells from Human Peripheral Blood
Bone marrow contains two types of stem cells: the hematopoietic stem cell
(HSC) and the mesenchymal stem/stromal cell (MSC). Previous dogma held that HSCs
gave rise exclusively to blood lineage cells, while MSCs were capable of giving rise to
mesenchymal cell types including adipocytes, endothelial cells, chondrocytes,
osteoblasts/osteocytes, fibroblasts, and microglial cells77–83. Our lab has shown that
HSCs

are

also

capable

of

giving

rise

to

mesenchymal

cells-

adipocytes,

osteochondrogenic cells, fibroblasts/myofibroblasts, and microglial and perivascular cells
of the brain74,84–87. Therefore, we are particularly interested in the plasticity and potential
of HSC-derived cells.

Thus, it is imperative for our studies to examine populations

enriched for HSC-derived cells in order to diminish MSC contamination and its
corresponding effects. As one of the characteristics of a MSC is adherence to plastic,
we obtained the non-adherent population of cells from peripheral blood and cultured
these for our studies in order to enrich for an HSC-derived population76. To determine
whether our non-adherence culture method was optimal towards enriching for cells of an
HSC origin in the peripheral blood, flow cytometric analysis of expression of CD45
(common leukocyte antigen), a known marker of hematopoietic cells, was performed.
Peripheral blood was obtained from normal control subjects, then mononuclear
cells (MNCs) were isolated via density centrifugation.

MNCs were saved for flow

cytometric analysis or plated on a T25 tissue culture treated flask and incubated at 37°C
in free gas exchange at 5% CO2. After either a 2 hour or 20 hour incubation period, the
non-adherent MNCs were removed from culture for flow cytometric analysis. As shown
in Figure 3, obtaining the non-adherent population of MNCs is sufficient for enriching for
CD45+ HSC-derived cells and this enrichment increases with increasing culture time
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from 2 hrs to 20 hrs. Thus, by isolating and culturing the non-adherent population of
peripheral blood MNCs, we selected for an enriched population of HSC-derived cells to
be used in our studies.

31

A.

Norm 2 PB

Norm 1 PB

Control:
CD45-V500 FMO

MNCs

2 hr NAd

20 hr NAd

CD45+
0.089

CD45+
75.9

CD45+
84.3

CD45+
94.1

CD45+
0.089

CD45+
51.1

CD45+
88.8

CD45+
92.3

B.
100

MNC
2 hr NAd
20 hr NAd

%CD45+

80
60
40
20

2
or
m
N

N

or
m

1

0

Figure 3. Enrichment of hematopoietic-derived cells from the NAd population of
MNCs. (A) Total peripheral blood (PB) mononuclear cells (MNCs) compared to the nonadherent (NAd) population of MNCs derived after culture for either 2 hours (2 hr NAd) or
20 hours (20 hr NAd) from two different normal control subjects (Norm 1 PB and Norm 2
PB) were stained for CD45, the common leukocyte antigen, and analyzed via flow
cytometry. CD45 FMO was used as a control for gating strategy. (B) Graphical depiction
of flow cytometric data from each normal control subject.
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Characterization of Cultured CFPs from Human Peripheral Blood
In order to determine if our isolation and culture methods were sufficient for
obtaining fibroblasts from human peripheral blood (CFP-derived fibroblasts), we cultured
the non-adherent population of MNCs, shown to be enriched for hematopoietic-derived
cells,

from

normal

control

subjects

(n=3)

for

14-21

days

then

performed

immunohistochemical analysis for the following fibroblast markers: collagen I (Col I),
vimentin, and alpha smooth muscle actin (αSMA) (Representative data shown in Figure
4A).

Because there is no single specific fibroblast marker, we chose a panel of

fibroblast markers to examine whether our cultured cells were indeed displaying a
fibroblastic phenotype. We then performed the same immunohistochemical analysis on
patients with metastatic STS (n=3) in order to determine whether CFP-derived
fibroblasts were also present in the peripheral blood of patients with STS tumor burden
(Representative data shown in Figure 4B). Our data demonstrate the presence and
feasibility of isolating CFPs from human peripheral blood, in both normal controls and
patients with STS, and show that once cultured, CFPs were positive for Col I, Vimentin,
and αSMA, all markers of fibroblasts.
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Figure 4. Immunohistochemical analysis of cultured CFPs. (A) Representative
image of CFPs cultured from the peripheral blood of a normal control subject. Cells were
stained with antibodies for Col I (red; B), Vimentin (green; C,H), and αSMA (red; G).
Nuclei were stained with Hoechst dye (blue). Merged images for Col I and Vimentin
(D,E) and αSMA and Vimentin (I,J). Secondary only control staining for Col I/ αSMA (L)
and Vimentin (M).

(B) Representative image of CFPs cultured from the peripheral
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blood of a patient with metastatic STS (leiomyosarcoma). Cells were stained with
antibodies for Col I (red; B), Vimentin (green; C,G), and αSMA (red; F). Nuclei were
stained with Hoechst dye (blue). Merged images for Col I and Vimentin (D) and αSMA
and Vimentin (H). Secondary only control staining for Col I/ αSMA (J) and Vimentin (K).
Mag bars = 25 µm.
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After confirming our ability to isolate and culture CFP-derived fibroblasts from the
peripheral blood of normal control subjects and patients with STS, we aimed to further
characterize these cultured CFPs through examination of mRNA expression levels for
genes associated with a fibroblast-like phenotype via RT-qPCR (Figure 5). Our data
indicate that we indeed isolated CFPs from both STS patients and control subjects, as
they revealed mRNA expression of the following hematopoietic and fibroblastic markers:
CD45, DDR2, Col1, Vimentin, and αSMA. Our data further indicated differences between
STS patients and control subjects as CD45, Collagen I (Col1), and Vimentin expression
was decreased, while DDR2 expression was increased in CFPs from patients with STS
as compared to CFPs from normal control subjects. No significant difference in αSMA
expression was found between the two cohorts.

*
*

*

*

Figure 5. RT-qPCR characterization of CFPs from patients with STS
RT-qPCR of mRNA expression levels in cultured CFPs from patients with STS (Pt CFP)
and normal control subjects (Norm CFP) normalized to HPRT. Each bar represents
averaged expression for each group with n=4. *P<0.05 compared to Norm CFP.
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Quantification of CFPs in Peripheral Blood of Normal Control Subjects and STS Patients
We then sought to determine whether CFP numbers varied in the circulation of
patients with STS compared to normal control subjects without known malignancies.
Peripheral blood MNCs were isolated (without culture), then stained with antibodies for
CD45 (common leukocyte antigen) and discoidin domain receptor 2 (DDR2, a receptor
for collagen) and analyzed via flow cytometry (Figure 6).

We define our CFPs as

CD45+ DDR2+, as these two markers indicate both the hematopoietic origin and
fibroblastic phenotype of our cell population. Flow cytometric analysis of five normal
control subjects without known malignancies was compared to four STS patients, three
of whom had metastatic disease (Table 4.4). Flow cytometric analysis revealed no
significant difference in the average percentage of CFPs present within the peripheral
blood of patients with STS (mean ± standard deviation: 0.54 ± 0.20) compared to normal
control subjects (mean ± standard deviation: 0.45 ± 0.51). However, when examining
individual data points it is apparent that patient 1, who had metastatic STS without
treatment, had the highest percentage of CD45+ DDR2+ CFPs with a 2.3 fold increase
compared to average normal control. Patient 1 showed an increased percentage of
CFPs over two other patients (patient 3, 4) who also had metastatic STS, but were
undergoing chemotherapeutic treatment (with Yondelis).

It was also noted that the

patient without evidence of metastatic disease (patient 2) had a lower percentage of
CFPs than either of the patients with metastasis or normal controls.
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A.

B.
Sample
Norm 1
Norm 2
Norm 3
Norm 4
Norm 5
Pt 1
Pt 2
Pt 3
Pt 4

% CD45+ DDR2+
0.58
0.23
0.65
0.76
0.49
1.21
0.096
0.31
0.20

Figure 6. CFP quantification in human peripheral blood. Peripheral blood (PB)
mononuclear cells (MNCs) were isolated from normal control subjects (Norm MNCs) and
patients with Soft Tissue Sarcoma (Pt MNCs) and stained with antibodies for CD45 and
DDR2. The percentage of CD45+ DDR2+ cells (CFPs) was analyzed via flow cytometry.
(A) Summary of flow cytometric data is shown as % CD45+ DDR2+. (B) % CFPs shown
for each subject.

Table 4.4 Patient Profiles for Figure 6
Patient
1

Age
61

2

66

3

72

4

52

Diagnosis
Metastatic Synovial
Sarcoma
Pleiomorphic
Undifferentiated
Sarcoma without
evidence of metastases
Metastatic
Angiosarcoma
Metastatic Synovial
Sarcoma
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Current Treatment
None
None

Yondelis
Yondelis

Section 5: Discussion
Our lab previously demonstrated that HSCs are a novel source for CAFs and
their blood precursors, CFPs, and that murine CFPs (CD45+ DDR2+) were present in the
peripheral blood and increased with tumor burden13,14. However, the identification and
characterization of human CFPs in cancer, specifically soft tissue sarcoma, had not
been established. Thus, the goal of this study was to isolate, characterize, and quantify
CFPs in patients with STS. Our data revealed that our isolation technique for obtaining
the non-adherent population of MNCs was sufficient for enriching for CD45+ HSCderived cells and that this enrichment was enhanced with increasing culture time (from 2
hrs to 20 hrs). Immunohistochemical analysis of the cultured non-adherent MNC
population from the peripheral blood of patients with metastatic STS and normal control
subjects revealed CFPs were present in this fraction of human peripheral blood as these
cultured cells displayed fibroblastic marker expression for collagen 1 (Col I), alpha
smooth muscle actin (αSMA), and vimentin. Fibroblasts are known to secrete Col I, an
important protein found in the extracellular matrix (ECM) and to express vimentin, a
member of the intermediate filament family. αSMA is implicated in cell contractility and
motility and fibroblast expression of αSMA has been associated with a myofibroblast or
activated phenotype and is upregulated by TGF-β, particularly in the tumor
environment88,89.
RT-qPCR data revealed differences between STS patients and normal control
subjects in mRNA expression of hematopoietic and fibroblastic markers. The decrease
in CD45 expression in CFPs from patients with STS as compared to normal control
subjects is of interest as studies have shown that CD45 is downregulated as fibrocytes
(a cell type similar to that of CFPs) differentiate90,91. This may indicate that CFPs from
patients with STS are further differentiated compared to CFPs from normal control
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subjects. The increase in DDR2 expression in patients with STS compared to control
subjects is also of interest as studies have shown that fibroblast spreading and migration
is dependent upon DDR2

92–94

. Additionally the decrease in Col1 expression, a ligand for

DDR2, may cause DDR2 on the CFPs to not be saturated with collagen via autocrine
signaling, potentially freeing DDR2 to bind to collagen at sites further away (such as the
lung- a common site of STS metastasis), aiding in CFP migration. Thus, our RT-qPCR
data may suggest that CFPs from patients with STS display a more differentiated and
migratory phenotype compared to normal control subjects.
Flow cytometric analysis of CD45+ DDR2+ cells revealed no significant difference in
the average percentage of CFPs present within the peripheral blood of patients with STS
compared to normal control subjects. However, it was found that patient 1 who had
metastatic STS without treatment showed the highest percentage of CD45+ DDR2+
CFPs than any of the subjects, with a 2.3 fold increase compared to average normal
control. Patients with metastatic STS were shown to have a higher percentage of CFPs
compared to a patient with non-metastatic STS (patient 2). Patient 2, without evidence of
metastatic disease, showed a lower percentage of CFPs than patients with metastatic
disease and even that of normal control subjects. Given that this was the only nonmetastatic patient in this data set, it remains to be determined if this CFP profile would
hold for other patients without evidence of metastatic disease. If so, it may indicate that
CFPs are a unique marker for the metastatic phase of disease.

Of further interest is

that patient 1 showed an increased percentage of CFPs over two other patients (patient
3, 4) who also had metastatic STS, but were undergoing chemotherapeutic treatment.
This may suggest chemotherapeutic treatment functions in part by suppressing the CFP
population, reinforcing the idea of an important role for CFPs in metastatic disease. This
data may also implicate percentage of CFPs as a biomarker for response to
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chemotherapeutic treatment in metastatic disease. Given the small number of samples,
further analysis of patients with metastatic STS receiving chemotherapeutic treatment
should be compared to patients without treatment in order to determine if this trend is
applicable to the majority of STS patients and whether this trend is associated with
certain STS subtypes. This knowledge would be especially efficacious in the treatment
of patients with STS because chemotherapeutic agents have exhibited varied response
rates, making it a challenge for physicians to identify which patients will benefit from
treatment.
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Chapter 5: Specific Aim 2
To determine the role of CFP-derived fibroblasts from patients with soft tissue sarcoma
in promoting proliferation, migration, and invasion of sarcoma cells.

Section 1: Introduction
Cancer-associated fibroblasts (CAFs), some of which are potentially derived from
circulating fibroblast precursors (CFPs), are mature tissue fibroblasts associated with the
solid tumor and have been shown to promote tumor progression by stimulating
angiogenesis, cancer cell growth, invasion and metastasis, and through evasion of the
immune response.

CAFs implement these effects by production of various growth

factors (such as VEGF, a potent angiogenesis inducer), matrix metalloproteinases (such
as MMP9 which degrades collagen and fibronectin, allowing the tumor cell to transverse
the basement membrane), and through production of chemokines and cytokines. Our
lab has shown that CFPs, a precursor to CAFs, contribute to tumor growth and migrate
in response to monocyte chemoattractant protein-1 (MCP-1), suggesting that CFPs may
play a direct role in promoting the progression and metastasis of solid tumors. We,
therefore, aimed to test the hypothesis that CFP-derived fibroblasts play a functional role
in soft tissue sarcoma metastasis through production of specific chemokine, cytokine,
and growth factors involved in promoting the proliferation, migration, and invasion of
sarcoma cells.

Section 2: Hypothesis
We hypothesized that CFP-derived fibroblasts, through production of specific
chemokine, cytokine, and growth factors promoted proliferation, migration, and invasion
of sarcoma cells.
42

Section 3: Materials and Methods
Cell Culture of Human Peripheral Blood
Peripheral blood (9-15 mL) was drawn from patients with soft tissue sarcoma and
from control subjects (All Cells #WB001-NH) without any known malignancies and
collected in sodium heparin-coated vacutainer tubes (BD #367878). Mononuclear cells
were isolated via density centrifugation with Lympholyte H (Cedarlane #CL5010) and
plated on a T25 tissue culture treated flask (Corning #430639) and incubated at 37°C in
free gas exchange at 5% CO2. After a 20 hour incubation period, non-adherent HSCderived mononuclear cells were removed and plated on 4-well fibronectin-coated tissue
culture plates (Corning #354559) for 14-21 days at a concentration of 6x105 cells per
well in 1 mL of Minimum Essential Medium α (MEMα) (Life Technologies #12561)
supplemented with 20% fetal bovine serum (Atlanta Biologicals, lot #6005C) and
penicillin streptomycin in order to promote the differentiation of CFPs into fibroblasts
(CFP-derived fibroblasts). Cells were then gently washed 3 times in MEMα and serum
starved for 24 hours in 0.5 mL MEMα per well (6x105cells/ well). CM was collected and
filtered to remove debris, then used for proliferation, migration, and invasion experiments
(Figure 7).

In vitro Generation of Tumor-Exposed CFPs
HT-1080 Conditioned Media (CM) was obtained by culturing 3x106 HT-1080
cells in a T75 tissue culture plate (Corning #353136), then cells were gently washed 3
times in MEMα to remove residual growth media, and cells were serum starved in 10 mL
MEMα (Life Technologies #12561) for 24 hours. After 24 hours, HT-1080 CM was
collected and filtered to remove debris.
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Peripheral blood was obtained from control subjects (All Cells #WB001-NH)
without any known malignancies and collected in sodium heparin-coated tubes.
Mononuclear cells were isolated via density centrifugation with Lympholyte H (Cedarlane
#CL5010) and plated on a T25 tissue culture treated flask (Corning #430639) and
incubated at 37°C in free gas exchange at 5% CO2. After a 20 hour incubation period,
non-adherent HSC-derived mononuclear cells were removed and plated on 4-well
fibronectin-coated tissue culture plates (Corning #354559) at a concentration of 6x105
cells per well in 1 mL of either MEMα (Life Technologies #12561) supplemented with
20% fetal bovine serum (Atlanta Biologicals, lot #6005C) and penicillin streptomycin
(Normal Control) or HT-1080 CM supplemented with 20% fetal bovine serum (Atlanta
Biologicals, lot #6005C) and penicillin streptomycin (Tumor-Exposed) and cultured for
growth of CFP-derived fibroblasts. Normal Control and Tumor-Exposed CFP-derived
fibroblasts were cultured in their designated media for up to 15 days with media renewal
every 3 days after the first week of culture. Normal Control and Tumor-Exposed cells
were then gently washed 3 times in MEMα and serum starved for 24 hours in 0.5 mL
MEMα per well (6x105 cells/well). CM was then collected and filtered to remove debris,
then used for proliferation, invasion, and cytokine array experiments as an in vitro model
of Tumor-Exposed CFPs (Figure 8, 9).

Proliferation Assay
1x103 HT-1080 (human fibrosarcoma) cells were plated in triplicate in 150 µL of
CM in individual wells of a 96-well tissue culture treated plate (Corning #3799).
Proliferation was measured using CyQuant Direct Cell Proliferation Assay (Invitrogen
#C35011) according to manufacturer’s protocol.
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Fluorescence was read at 480nm

excitation and 535nm emission on a BioTek Synergy HT microplate reader using Gen 5
software.

Migration and Invasion Assay
Prior to migration assay, inserts (Costar #3422 transwell permeable support
8.0µm polycarbonate membrane) were coated with fibronectin (5 µg/mL) and incubated
1 hour at 37°C, then air dried. 600 µL of conditioned media was placed in the bottom of
individual wells (with 3 replicate wells) of a 24-well non-tissue culture treated plate
(Corning #351147), then 1.5×104 HT-1080 (human fibrosarcoma) cells in 100 µL αMEM
were placed in each insert.
Prior to invasion assay, invasion chambers (BD #354480 BioCoat BD
Matrigel Invasion Chamber, 8.0 µm PET Membrane) were allowed to come to room
temperature. Then inserts were rehydrated for 2 hours at 37°C in warm DMEM. After
rehydration, 750 µL of conditioned media was placed in bottom of individual wells (with
each sample plated in triplicate wells) of a 24-well non-tissue culture treated plate
(Corning #351147), then 5.0×104 HT-1080 cells in 500 µL αMEM was placed in each
insert.
After 8 hours (migration) or 22 hours (invasion) incubation at 37°C in free gas
exchange at 5% CO2, inserts were removed and the top of each insert was gently
scrubbed with a q-tip to remove cells that have not invaded through the membrane.
Inserts were then stained with the Diff-Quik stain set (Siemens #B4132-1A). 10 high
powered fields were counted on each insert using a Nikon Eclipse Ti-U microscope with
NIS-Elements BR3.2 software.
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Cytokine Array
Levels of cytokines in CM were measured with the Human XL Cytokine Array Kit
(R&D Systems #ARY022) according to manufacturer’s protocol with the use of 500 µL
CM in 1 mL Array Buffer 6 for each membrane. Membranes were then exposed to
autoradiography film (MidSci #EBNU2) and average pixel density for each cytokine was
analyzed using ImageJ software (NIH).

Human Consent
Peripheral blood was obtained after informed consent was given and subjects
were enrolled into our Institutional Review Board approved study (CTO 101576) through
the MUSC Hollings Cancer Center. All subjects consented were over 18 years of age
and had soft tissue sarcoma, either metastatic or non-metastatic.

Statistical Data Analysis
Data are presented as mean ± standard deviation of the value. To compare
variables between 2 groups, the two-tailed unpaired Student t-test was performed, with
significance determined as p<0.05.
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Section 4: Results
CFP-derived fibroblasts from patients with STS promote HT-1080 fibrosarcoma
proliferation, migration, and invasion
HSC-derived CFPs are a potential source for CAFs, which are known to promote
tumor cell proliferation, migration, and invasion, all essential elements of metastatic
progression95–97.

Although CAFs have not been investigated in STS progression or

metastasis, given our identification of CFPs in patients with STS, we sought to
investigate the functionality of these cells, particularly in relation to their ability to support
tumor advancement. In order to examine whether CFP-derived fibroblasts from patients
with STS promote tumor cell progression, conditioned media (CM) was collected from
cultured CFP-derived fibroblasts from either patients with STS or normal control subjects
and assays were performed to analyze the ability of conditioned media from CFPderived fibroblasts to promote HT-1080 (human fibrosarcoma) cell proliferation,
migration, and invasion. Due to the rarity and heterogeneity of STS, our studies were
performed on CFP-derived fibroblasts from patients with various types of STS. As there
are not cell lines for most types of STS, we utilized the HT-1080 cell line from ATCC as a
standard cell line in each of our assays. Diagnosis and treatment status of patients is
found in Table 5.1.
One of the hallmarks of cancer progression is the ability of a tumor cell to sustain
proliferation97. Tumor cells continually proliferate through production of growth factor
ligands, resulting in autocrine stimulation or through secretion of factors to normal cells
in the surrounding environment, which may then respond to the tumor by supplying it
with growth factors95. Our studies found that CFPs from patients with STS were capable
of promoting HT-1080 tumor cell proliferation over αMEM (Figure 7A). CFPs from one
patient in particular, patient 8, who had metastatic myxoid liposarcoma, significantly
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enhanced HT-1080 tumor cell proliferation over normal control subjects during all 3 time
points. CFPs from patient 15 and 16, who also had metastatic myxoid liposarcoma
showed significant increases in HT-1080 proliferation after 72 hours, potentially
suggesting CFPs from patients with the myxoid liposarcoma subtype of STS have
enhanced ability to promote sarcoma tumor cell proliferation.
Another hallmark of tumor progression is the activation of invasion and
metastasis97. This requires chemotactic migration of tumor cells, along with the ability of
the tumor cell to protrude its cell membrane while remodeling and degrading the
extracellular matrix (ECM)98.

During invasion, matrix degrading proteases, either

produced by the tumor cell or recruited inflammatory cells present in the tumor
microenvironment, produce MMPs that play an important role in tumor escape97. In order
to examine whether CFPs were capable of enhancing sarcoma migration and invasion,
transwell assays were performed using CFP conditioned media (CM) as a
chemoattractant. Our data indicate that CFPs from two of the three patients with STS
promoted HT-1080 tumor cell migration over normal control (Figure 7B). Furthermore,
CM from CFPs from all patients with STS showed increased HT-1080 invasion over
αMEM. We found enhanced HT-1080 invasion toward CFP CM in 4 out of 9 patients with
STS over normal control subjects (Figure 7C, asterisks).

48

A.

*

*
*

*
**

*

B.

C.

*

*
* *
*
*

Figure 7. CFPs from patients with STS promote HT-1080 sarcoma cell
proliferation, migration, and invasion. Conditioned media (CM) from cultured CFPderived fibroblasts from patients (Pt) with STS (individual results) and normal (Norm)
control subjects (averaged, n=4) was examined in vitro for ability to promote HT-1080
fibrosarcoma proliferation after 24, 48 and 72 hours (A), ability to promote HT-1080
migration (B) through 0.8µm pore fibronectin coated transwells and invasion (C) through
0.8µm pore matrigel coated transwells. 1% FBS served as positive control. For
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proliferation assay, fold change over αMEM is presented. * P<0.05 compared to normal
CFP (A,B,C). Note in C, all patients showed significant increase (p<0.05) over αMEM
control.

Table 5.1 Patient Profiles for Figure 7
Patient #
6

Age
42

8

44

9

44

10

48

14

41

15

52

16

48

17

55

23

79

Diagnosis
Metastatic Uterine
Leiomyosarcoma
Metastatic Myxoid
Liposarcoma
Metastatic Mixed
Mullerian tumor
Metastatic Synovial
Sarcoma
Metastatic Pleomorphic
Sarcoma
Metastatic Myxoid
Liposarcoma
Metastatic Myxoid
Liposarcoma
Metastatic
Leiomyosarcoma
Metastatic Spindle Cell
Sarcoma
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Current Treatment
Yondelis
Yondelis
Yondelis
Temsirolimus
Yondelis
Yondelis
Yondelis
Yondelis
None

In vitro tumor-exposed CFPs promote HT-1080 fibrosarcoma invasion and display
altered cytokine profiles compared to control CFPs.
Our in vitro data with CM from patients with STS suggests CFP-derived
fibroblasts promote HT-1080 proliferation, migration, and invasion over αMEM, although
not all patient CFPs show a significant difference in ability to do so compared to normal
control CFPs (Figure 7). A complication of these studies was the use of the HT-1080
fibrosarcoma cell line for assays with STS patients that had other types of STS, meaning
the HT-1080 fibrosarcoma tumor cell type used in the previous assays did not match the
tumors of the individual STS patients. The rarity and heterogeneity (over 100 different
subtypes) of STS means there are few cell lines available and cell lines have not been
created for each STS subtype. Thus, we aimed to create an in vitro culture method for
generating tumor-exposed CFPs (an in vitro analogue of CFPs derived from patients
with STS) that could then be used in proliferation and invasion assays with tumor cells of
the same subtype to which the CFPs were exposed to.
Peripheral blood was obtained from normal control subjects without any known
malignancies and cultured for growth of CFP-derived fibroblasts in either αMEM
supplemented with 20% fetal bovine serum and penicillin streptomycin (normal control)
or HT-1080 CM supplemented with 20% fetal bovine serum and penicillin streptomycin
(tumor-exposed). Normal control and tumor-exposed CFP-derived fibroblasts were
cultured in their designated media for up to 15 days with media renewal every 3 days
after the first week of culture. CM was then collected from normal control and tumorexposed CFPs for use in proliferation, invasion, and cytokine array assays (Figure 8).
Because CFPs are present in the peripheral blood, our chosen method for generating in
vitro tumor-exposed CFPs was co-culture of CFPs with tumor CM, rather than direct cellto-cell contact with tumor cells as may be important for studies of tumor-stroma
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interactions. Exposure to tumor CM is therefore a better model for our studies in order
to study CFP response to tumor secreted proteins in the peripheral blood.
Our data indicated that tumor-exposed CFP CM promoted HT-1080 tumor cell
proliferation over αMEM and 1% FBS positive control, although not significantly over
normal control CFP CM. Tumor-exposed CFP CM was further found to promote HT1080 invasion over normal control CFPs (2.25 fold increase), implicating that CFPs may
play a more important role in tumor invasiveness through production of matrix degrading
proteins than through secretion of growth factors involved in tumor cell proliferation.
Cytokine array analysis revealed an altered cytokine profile of tumor-exposed
CFP CM compared to normal control CFP CM (Figure 9). Factors found to be increased
more than 2 fold in tumor-exposed CFP CM included CD14, Complement Factor D,
EMMPRIN, CXCL5, IL-8, MCP-1, MIF, Serpin E1, and uPAR, with MCP-1 having the
highest expression. Additionally, RANTES, although lowly expressed in control CFPs,
was found to be decreased in tumor-exposed CFP CM. Our cytokine array data suggest
CFP exposure to tumor secreted factors found in HT-1080 CM alters the CFP
expression profile. Tumor crosstalk between cells of the stroma and cells in circulation
is known to play an important role in tumor progression.

Our data implicate this

crosstalk is causing enhanced expression in CFPs of proteins important to tumor
advancement.
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HT-1080 CM
supplemented
with 20% FBS

Tumor-exposed
CFPs
Normal CFPs
Tumorexposed
CFPs and
Control
CFPs serum
starved for
24 hrs.

CFPs cultured in designated
media for 15 days, with media
renewal every 3 days after the
first week of culture
αMEM
supplemented
with 20% FBS

Conditioned
Media
collected and
used for
proliferation,
invasion, and
cytokine array
assays

Control
CFPs
Normal CFPs

Figure 8. In vitro generation of tumor-exposed CFPs. Tumor-exposed CFPs were
generated in vitro by culturing normal CFPs in HT-1080 fibrosarcoma conditioned media
(CM) supplemented with 20% FBS for 15 days with media renewal every 3 days after
the first week of culture. Control CFPs were cultured in αMEM supplemented with 20%
FBS for 15 days with media renewal every 3 days after the first week of culture. Media
was then removed from cells, and cells were serum starved for 24 hours to obtain
conditioned media to be used in subsequent assays.
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Figure 9. In vitro generated tumor-exposed CFPs promote invasion of tumor cells
along with an altered cytokine profile compared to control CFPs. Conditioned
media (CM) was collected from normal control CFP-derived fibroblasts (Norm CFP) or
from norm CFP-derived fibroblasts exposed to HT-1080 CM (Tumor-exposed CFP) and
examined in vitro for ability to promote HT-1080 fibrosarcoma proliferation after 24, 48
and 72 hours (A) and ability to promote HT-1080 invasion (B) through 0.8µm pore
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fibronectin matrigel coated transwells after 22 hours. 1% FBS served as positive control.
CM from Norm Control CFP and Tumor-exposed CFPs was subjected to cytokine array
analysis and average pixel density was analyzed by ImageJ software (C). Fold change
of average pixel density of Tumor-exposed CFP over Norm CFP CM was then assessed
(D). * P<0.05 compared to normal control CFP CM (A,B).
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Section 5: Discussion
Cancer-associated fibroblasts (CAFs), have been shown to promote tumor
progression in numerous tumor types, although they have not be investigated in STS.
CAFs accelerate tumor progression by stimulating angiogenesis, cancer cell growth,
invasion and metastasis, and through evasion of the immune response.

CAFs

implement

matrix

these

effects

by

production

of

various

growth

factors,

metalloproteinases (such as MMP9 which degrades collagen and fibronectin, allowing
the tumor cell to transverse the basement membrane), and through production of
chemokines and cytokines.

Our lab has shown that CFPs, a precursor to CAFs,

contribute to tumor growth and migrate in response to monocyte chemoattractant
protein-1 (MCP-1), suggesting that CFPs may play a direct role in promoting the
progression and metastasis of solid tumors14. It was, therefore, the goal of our study to
test whether CFP-derived fibroblasts play a functional role in soft tissue sarcoma
metastasis through production of specific chemokine, cytokine, and growth factors
involved in promoting the proliferation, migration, and invasion of sarcoma cells.
Our data suggest that CFPs from both patients with STS and normal control
subjects promoted sarcoma tumor cell proliferation, migration, and invasion over αMEM
(control media). CFPs from some patients with STS further showed enhanced ability to
promote tumor cell proliferation, migration, and invasion over normal control CFPs.
CFPs from the three patients with metastatic myxoid liposarcoma further displayed
enhanced ability to promote HT-1080 proliferation over normal control subjects, with one
of these patients (patient 8) showing an appreciable enhancement even over other STS
patients. Because we often receive a limited amount of peripheral blood from patients,
not all patients had enough cells to conduct proliferation, migration, and invasion assays.
However, CFPs for patients 8, 9, and 10 were able to be analyzed for ability to promote
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HT-1080 proliferation, migration, and invasion. Patient 8, with metastatic myxoid
liposarcoma and Yondelis treatment showed increased ability to promote proliferation
and migration over normal controls. Patient 9, with metastatic mixed mullerian tumor,
showed increased ability to promote migration over normal controls, whereas patient 10,
with metastatic synovial sarcoma and Temsirolimus treatment did not show a significant
increase over normal control subjects in any assay.

Acquiring more patients with

varying STS subtypes and chemotherapeutic treatments would allow us to analyze
whether these effects are subtype or treatment related and allow us to determine
whether these results correlate with patient prognosis.
A complication of our studies using the HT-1080 fibrosarcoma cell line for
proliferation, migration, and invasion assays was that STS patients had STS subtypes
that did not match that of the HT-1080 fibrosarcoma tumor cell being used in the
previous assays. Thus, we aimed to create an in vitro culture method for generating
tumor-exposed CFPs. Our in vitro generated tumor-exposed CFPs displayed an
increased potential to promote tumor proliferation and invasion, with invasive ability
being significant over normal control CFPs. The in vitro generated tumor-exposed CFPs
revealed altered cytokine profiles compared to normal control CFPs with many proteins
of interest in regards to tumor progression increased over that of normal control CFPs.
Cytokines including EMMPRIN, MCP-1, IL-8, uPAR, and Serpin E1 showed increased
expression in tumor-exposed CFPs compared to normal control CFPs. EMMPRIN is
known to induce MMP synthesis by both tumor cells and fibroblasts, potentiating tumor
cell invasiveness in the tumor microenvironment and leading to the induction of
angiogenesis through stimulation of VEGF production99. The induction of MMP synthesis
through EMMPRIN may correlate with our invasion studies where tumor-exposed CFP
ability to promote tumor invasion was significantly increased compared to control CFPs.
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EMMPRIN has further been implicated as a prognostic marker for osteosarcoma when
combined with MMP expression100. MCP-1 was found to be an important cytokine
involved in trafficking of HSC-derived CFPs in our lab’s previous murine tumor studies14.
These studies revealed that CFP migration toward tumor conditioned media was MCP-1
dependent and it was shown that MCP-1 inhibition blocked tumor progression in vivo. IL8 is a proinflammatory cytokine and its expression has been shown to correlate with
tumorigenicity, angiogenesis, and metastasis in numerous in vivo tumor models101–103.
UPAR plays an important role in tumorigenicity, ECM degradation, and angiogenesis 104.
Studies have demonstrated that co-detection of uPAR in tumor tissue and serum
correlated with poor prognosis in patients with STS105. Serpin E1 is an inhibitor of tissue
plasminogen activator and urokinase (uPA, an ECM degrading protease). Human
fibrosarcoma cells transfected with Serpin E1 cDNA and then injected into the tail vein of
mice led to increased number and incidence of lung colonization106. Furthermore, it was
found that UPAR and Serpin E1 are induced in migratory cells and focalize to the
leading edge where they function in matrix restructuring and migration107. Therefore, our
data may indicate that after exposure to tumor cells, CFPs have enhanced abilities to
function in migration and matrix restructuring. Overall, our data suggest CFPs from
patients with STS promote tumor progression and in vitro generated tumor-exposed
CFPs have enhanced potential to promote tumor progression in relation to normal
control CFPs.
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Chapter 6: Conclusions and Future Directions
Soft tissue sarcomas (STS) are rare, heterogeneous malignant tumors of
mesenchymal origin that manifest in the connective tissues. The most lethal aspect of
sarcomas is their propensity for hematogenous dissemination leading to metastatic
disease. After development of distant metastases, the median survival for patients with
STS is merely 11 to 15 months1,2.

Therefore, gaining a better understanding of the

metastatic environment is essential to developing new therapies.
The tumor microenvironment has been implicated as an essential component for
metastatic progression and one of the most prominent cell types of the tumor
microenvironment is the cancer-associated fibroblast (CAF)3,4. Studies clearly show the
importance of CAFs in tumor advancement; however, their origins have not been
conclusively determined7–12. Our lab previously demonstrated a novel hematopoietic stem
cells (HSCs) source for CAFs and their blood precursors, circulating fibroblast precursors
(CFPs)13. Our lab further revealed that murine CFPs were present in peripheral blood,
found in vivo in the tumor stroma, and increased with increasing tumor burden, potentially
implicating CFPs in the progression of solid tumors14. Additionally, our lab revealed a HSC
origin for human CFPs15. The function of human CFPs in tumor metastasis, specifically
STS, however, had yet to be established. It was therefore, the goal of this study to isolate
and evaluate the peripheral blood of patients with STS in order to characterize CFPs in
these patients and determine their role in promoting STS tumor progression.
Our data indicated that our isolation technique for obtaining the non-adherent
population of MNCs was sufficient for enriching for CD45+ HSC-derived cells and that
this enrichment was enhanced with increasing culture time (from 2 hrs to 20 hrs).
Immunohistochemical analysis of the cultured non-adherent MNC population from the
peripheral blood of patients with metastatic STS and normal control subjects revealed
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CFPs were present in this fraction of human peripheral blood, displaying fibroblastic
marker expression for collagen 1 (Col I), alpha smooth muscle actin (αSMA), and
vimentin. In order to quantify CFPs in the peripheral blood of patients with STS, flow
cytometric analysis of CD45+ DDR2+ cells (CFPs) was performed. Although there was no
significant difference in the average percentage of CFPs present within the peripheral
blood of patients with STS compared to normal control subjects, changes in percentage
of CFPs were observed between individual STS patients with different treatment
regimens and disease stages.

The patient with metastatic disease without

chemotherapeutic treatment showed significant increase in percentage of CFPs over
other patients and control. Furthermore, patients with metastatic STS were shown to
have a higher percentage of CFPs compared to a patient with non-metastatic STS. This
data may suggest chemotherapeutic treatment functions in part by suppressing the CFP
population and may also implicate percentage of CFPs as a biomarker for response to
chemotherapeutic treatment.
We then went on to test whether CFP-derived fibroblasts played a functional role
in STS metastasis through the promotion of sarcoma cell proliferation, migration, and
invasion via production of specific chemokine, cytokine, and/or growth factors. Our data
suggest that CFPs from both patients with STS and normal control subjects promoted
tumor cell proliferation, migration, and invasion over αMEM (control media). CFPs from
some patients with STS further showed enhanced ability to promote tumor cell
proliferation, migration, and invasion over normal control CFPs. CFPs from patients with
metastatic myxoid liposarcoma (n=3) further displayed enhanced ability to promote HT1080 proliferation over normal control subjects, with one of these patients (patient 8)
showing an appreciable enhancement even over other STS patients.
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In vitro generated tumor-exposed CFPs additionally displayed an increased
potential to promote tumor proliferation and invasion, with invasive ability being
significant over normal control CFPs. In vitro generated tumor-exposed CFPs revealed
altered cytokine profiles compared to normal control CFPs with increased expression of
cytokines including EMMPRIN, MCP-1, IL-8, MIF, and uPAR, all known to play important
roles in tumor advancement. Together, our data demonstrate that CFPs promote the
invasive/metastatic potential of STS cells and suggest this is affected, at least in part, by
paracrine factors.
Future directions for the continued characterization of CFPs in patients with STS
should include increased STS patient accrual in order to identify differences in
percentage of CFPs based upon subtype, tumor stage (metastatic vs. non-metastatic),
and treatment. This knowledge will further enhance our understanding of the role of
CFPs in tumor progression and allow us to determine whether percentage of CFPs in
the peripheral blood correlates with STS subtype, tumor stage, and or treatment and if
this may be a predictor of patient response to chemotherapy. This knowledge would be
especially efficacious in the treatment of patients with STS because chemotherapeutic
agents have exhibited varied response rates, making it a challenge for physicians to
identify which patients will benefit from treatment.

Thus, it may spare patients who

would not respond to chemotherapy from possible toxicity-related side effects of
treatment. Additionally, it would be beneficial to examine STS tumor sections in primary
tumor and metastatic sites and identify presence of CFPs to determine whether CFP
numbers at the tumor site correspond with numbers of circulating CFPs in the peripheral
blood of patients with STS and whether these numbers are indicative of prognosis.
Tumor samples from patients with STS, as examined through Oncomine data, have
been shown to express DDR2 (one of the markers of a CFP), potentially implicating it as
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an important factor in this disease, justifying DDR2 as a focus for future studies108–113.
Further in vitro analysis of CFP function may also be performed to assess cytokine role
in tumor progression. For example, we saw increased EMMPRIN, MCP-1, IL-8, MIF,
and uPAR expression in our in vitro tumor-exposed CFPs compared to control CFPs and
through specifically blocking these cytokines in vitro, we may determine their role in
promoting sarcoma cell proliferation, migration, and invasion, potentially identifying
factors that could be blocked in the clinical setting during therapeutic treatment.
The end goal of these studies is improved outcome for patients with metastatic
STS. We hope that by better characterizing CFPs and their functional roles in patients
with STS, we may identify markers of disease progression that will assist clinicians in
determining which patients will possibly benefit from chemotherapeutic treatment, while
sparing those who will not benefit from possible toxicity-related side effects of tumor
treatment.
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